{"id":"NCT01377922","sponsor":"Catalyst Pharmaceuticals, Inc.","briefTitle":"A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)","officialTitle":"A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2011-06-22","resultsPosted":"2018-01-04","lastUpdate":"2018-01-04"},"enrollment":38,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lambert Eaton Myasthenic Syndrome"],"interventions":[{"type":"DRUG","name":"Amifampridine Phosphate","otherNames":["3,4-diaminopyridine phosphate","3,4-DAP phosphate"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Amifampridine Phosphate","type":"EXPERIMENTAL"}],"summary":"A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).","primaryOutcome":{"measure":"Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days","timeFrame":"Assessment at Baseline and Day 14","effectByArm":[{"arm":"Placebo","deltaMin":5.6,"sd":3.99},{"arm":"Amifampridine Phosphate","deltaMin":6.4,"sd":3.22}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0452"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States","France","Germany","Hungary","Poland","Russia","Serbia","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Asthenia","Fatigue","Nasopharyngitis","Otitis externa","Periodontitis"]}}